Compare · ATNM vs CLRB
ATNM vs CLRB
Side-by-side comparison of Actinium Pharmaceuticals Inc. (Delaware) (ATNM) and Cellectar Biosciences Inc. (CLRB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATNM and CLRB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ATNM is the larger of the two at $33.9M, about 1.6x CLRB ($20.7M).
- Over the past year, ATNM is down 45.4% and CLRB is down 76.5% - ATNM leads by 31.1 points.
- CLRB has been more active in the news (10 items in the past 4 weeks vs 7 for ATNM).
- ATNM has more recent analyst coverage (7 ratings vs 3 for CLRB).
- Company
- Actinium Pharmaceuticals Inc. (Delaware)
- Cellectar Biosciences Inc.
- Price
- $1.04-1.42%
- $2.51-3.09%
- Market cap
- $33.9M
- $20.7M
- 1M return
- -14.34%
- -25.30%
- 1Y return
- -45.43%
- -76.50%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NASDAQ
- IPO
- News (4w)
- 7
- 10
- Recent ratings
- 7
- 3
Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of clinical-stage antibody radiation-conjugates targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a range of hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas Pharma, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.
Cellectar Biosciences Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Latest ATNM
- Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
- Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
- Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
- Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
- Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
- Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
- Actinium Pharmaceuticals Inc. (Delaware) filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Actinium Pharmaceuticals Inc. (Delaware)
- Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
- Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
Latest CLRB
- SEC Form SCHEDULE 13G filed by Cellectar Biosciences Inc.
- SEC Form 424B3 filed by Cellectar Biosciences Inc.
- SEC Form EFFECT filed by Cellectar Biosciences Inc.
- Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
- Amendment: SEC Form S-1/A filed by Cellectar Biosciences Inc.
- SEC Form DEFA14A filed by Cellectar Biosciences Inc.
- SEC Form DEF 14A filed by Cellectar Biosciences Inc.
- SEC Form S-1 filed by Cellectar Biosciences Inc.
- SEC Form PRE 14A filed by Cellectar Biosciences Inc.
- Cellectar Biosciences Inc. filed SEC Form 8-K: Leadership Update